Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. (SHE:301584)
China · Delayed Price · Currency is CNY 28.71
-0.40 (-1.37%)
At close: Feb 12, 2026
SHE:301584 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 37,179 | 35,805 | 30,857 | 23,749 | 10,008 | 8,524 |
Other Revenue | -17,882 | -17,882 | -15,414 | -11,867 | 16.39 | 18.59 |
| 19,296 | 17,923 | 15,443 | 11,882 | 10,024 | 8,542 | |
Revenue Growth (YoY) | 24.95% | 16.05% | 29.97% | 18.54% | 17.35% | 23.08% |
Cost of Revenue | 17,793 | 16,602 | 14,264 | 10,986 | 9,339 | 8,030 |
Gross Profit | 1,503 | 1,321 | 1,179 | 896.48 | 685.03 | 512.09 |
Selling, General & Admin | 769.38 | 711.33 | 674.83 | 513.09 | 390.28 | 231.55 |
Research & Development | 26.86 | 26.02 | 30.62 | 13.62 | 4.79 | 2.7 |
Other Operating Expenses | 30.29 | 27.11 | 21.8 | 15.52 | 14.12 | 11.31 |
Operating Expenses | 850.6 | 778.86 | 736.54 | 573.42 | 423.58 | 272.02 |
Operating Income | 652.25 | 541.74 | 442.8 | 323.06 | 261.45 | 240.07 |
Interest Expense | -146.48 | -162.01 | -132.88 | -77.99 | -38.35 | -2.91 |
Interest & Investment Income | 7.75 | 8.42 | 7.79 | 6.44 | 7.25 | 5.75 |
Currency Exchange Gain (Loss) | 1.52 | 1.52 | 1.15 | -0.77 | -0.23 | 1.26 |
Other Non Operating Income (Expenses) | -6.13 | -7.56 | -0.58 | -3.9 | -0.33 | -0.83 |
EBT Excluding Unusual Items | 508.91 | 382.11 | 318.28 | 246.85 | 229.79 | 243.34 |
Impairment of Goodwill | - | - | - | - | - | -8.71 |
Gain (Loss) on Sale of Investments | -9.23 | -12.44 | -6.5 | -3.04 | -1.72 | -0.98 |
Gain (Loss) on Sale of Assets | 0.58 | 0.89 | 0.23 | 0.33 | -0.03 | 1.79 |
Asset Writedown | -9.41 | -0 | -0.28 | - | -0.04 | -0.2 |
Other Unusual Items | 7.32 | 7.32 | 3.44 | 5.15 | 3.01 | -7.25 |
Pretax Income | 498.16 | 377.87 | 315.18 | 249.29 | 231.01 | 227.99 |
Income Tax Expense | 138.51 | 104.08 | 88.31 | 60.07 | 55.25 | 60.4 |
Earnings From Continuing Operations | 359.66 | 273.79 | 226.88 | 189.22 | 175.76 | 167.59 |
Minority Interest in Earnings | -60.01 | -45.48 | -30.57 | -14.94 | -8.82 | -7.91 |
Net Income | 299.65 | 228.31 | 196.3 | 174.28 | 166.94 | 159.67 |
Net Income to Common | 299.65 | 228.31 | 196.3 | 174.28 | 166.94 | 159.67 |
Net Income Growth | 52.64% | 16.30% | 12.64% | 4.40% | 4.55% | -29.80% |
Shares Outstanding (Basic) | 356 | 357 | 357 | 356 | 355 | 355 |
Shares Outstanding (Diluted) | 356 | 357 | 357 | 356 | 355 | 355 |
Shares Change (YoY) | -0.28% | -0.05% | 0.35% | 0.14% | 0.10% | -0.15% |
EPS (Basic) | 0.84 | 0.64 | 0.55 | 0.49 | 0.47 | 0.45 |
EPS (Diluted) | 0.84 | 0.64 | 0.55 | 0.49 | 0.47 | 0.45 |
EPS Growth | 53.08% | 16.36% | 12.25% | 4.25% | 4.44% | -29.69% |
Free Cash Flow | 1,187 | 43.42 | -456.96 | -661.39 | -743.15 | -8.15 |
Free Cash Flow Per Share | 3.33 | 0.12 | -1.28 | -1.86 | -2.09 | -0.02 |
Gross Margin | 7.79% | 7.37% | 7.64% | 7.54% | 6.83% | 6.00% |
Operating Margin | 3.38% | 3.02% | 2.87% | 2.72% | 2.61% | 2.81% |
Profit Margin | 1.55% | 1.27% | 1.27% | 1.47% | 1.67% | 1.87% |
Free Cash Flow Margin | 6.15% | 0.24% | -2.96% | -5.57% | -7.41% | -0.10% |
EBITDA | 690.57 | 571.57 | 457.4 | 328.66 | 265.85 | 244.85 |
EBITDA Margin | 3.58% | 3.19% | 2.96% | 2.77% | 2.65% | 2.87% |
D&A For EBITDA | 38.32 | 29.83 | 14.59 | 5.61 | 4.39 | 4.78 |
EBIT | 652.25 | 541.74 | 442.8 | 323.06 | 261.45 | 240.07 |
EBIT Margin | 3.38% | 3.02% | 2.87% | 2.72% | 2.61% | 2.81% |
Effective Tax Rate | 27.80% | 27.54% | 28.02% | 24.09% | 23.92% | 26.49% |
Revenue as Reported | 19,296 | 17,923 | 15,443 | 11,882 | 10,024 | 8,542 |
Advertising Expenses | - | 1.49 | 1.41 | 0.63 | 0.71 | 0.31 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.